| It’s a tough job, and arguably just as important as the CEO: for the multinationals that rely on science and innovation, the top R&D executives in biopharma can bring home quite the pay package. You’d think salaries would track with the size of companies’ research budgets, but that’s not always the case—Regeneron’s George Yancopoulos tops our list, even though his company’s R&D spend doesn’t break the top 10. For more eye-watering paychecks and other surprises, as well as a microcosm of biopharma’s R&D world and this week’s top stories, read on below. | |
|
Featured Story | | | Tuesday, November 5, 2019 The top research and development executives from across biopharma are certainly not looking down the back of the sofa for change; most are earning around $7 million a year. But then the job is tough, and arguably just as important as the top CEO job, given how much companies rely on the strength of their R&D. |
|
|---|
|
Top Stories Of The Week Friday, November 1, 2019 Thanks to Pfizer's marketing push, diagnosis of the rare heart disease ATTR cardiomyopathy is on the rise—and its Vyndaqel treatment is zooming ahead. The med hauled in $156 million in the third quarter, way ahead of expectations, putting more pressure on Alnylam's Onpattro. Friday, November 1, 2019 Novo Nordisk has stopped development of its next-generation oral GLP-1 analog OG2023SC. The Danish drugmaker took the action after making progress with an enhanced version of its existing oral semaglutide formulation. Monday, November 4, 2019 Stryker is moving to acquire fellow devicemaker Wright Medical in a $4 billion play to gain a stronger foothold in fast-growing orthopedic segments. Friday, November 1, 2019 Eli Lilly’s Taltz and Novartis’ Cosentyx have been battling it out lately in the next-gen psoriatic arthritis field. But Lilly’s drug has a big win under its belt that Novartis can’t tout. Cosentyx failed to outdo AbbVie behemoth Humira in a head-to-head trial in active psoriatic arthritis patients. Monday, November 4, 2019 With global recalls of heart burn med Zantac ongoing, the FDA is hoping to restore consumer confidence. Worried about higher-than-recommended levels of a possible carcinogen in the pills? They're no more dangerous than a grilled ribeye, the agency said Monday. Tuesday, November 5, 2019 Daiichi Sankyo has started legal action against Seattle Genetics. The case centers on linker technology used in antibody-drug conjugates (ADCs) including Daiichi’s AstraZeneca-partnered DS-8201. Monday, November 4, 2019 Until today, Halozyme worked under a two-pillar strategy, with licensing dollars from its Enhanze drug delivery technology bankrolling its cancer pipeline. Now, with the failure of its lead program in pancreatic cancer, the company is pulling the plug on drug development to focus solely on Enhanze and cutting 55% of its staff in the process. Tuesday, November 5, 2019 Mylan is focused on closing its merger with Pfizer's Upjohn next year. But after that deal closes, the pumped-up company should have the firepower for more M&A deals, an exec said. Meanwhile, the company canned 350 products in a cleanout of its current portfolio. Wednesday, November 6, 2019 India’s Aurobindo, which has yet to meet FTC terms to complete a $1 billion deal to buy a significant chunk of Sandoz U.S. generics business, also continues to struggle to meet FDA terms for its manufacturing plants. Monday, November 4, 2019 Harvard synthetic biology pioneer George Church generated some buzz last year when he co-founded Rejuvenate Bio with the goal of reversing aging with gene therapy. Now, he and his co-founders say they have compelling early evidence in mice that they can use the technology to relieve or reverse Type 2 diabetes, obesity, and heart and kidney failure. Enrollment Showcase Resources Sponsored by: Veeva Systems Medical Affairs 2025 brings together leading perspectives from AstraZeneca, Bristol-Myers Squibb, Merck, Lilly, and other innovative life sciences organizations on key challenges impacting medical affairs and a roadmap for success in the coming decade. Sponsored by: SHYFT Analytics This whitepaper provides a snapshot of where the biopharma industry is now, where it's heading, and how companies are allocating their resources to adapt & grow. Sponsored by: IBM Watson Health Acknowledging various stakeholder networks, as well as recognizing variances within the regulatory environment, we believe, is essential for companies looking to uncover the right decision-makers in support of biologics or biosimilars. Learn more. Sponsored by: ON24 Discover solutions to the most common challenges faced by medical device companies. Sponsored by: Eli Lilly and Company in partnership with Xcenda Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system. Sponsored by: Clarivate Analytics 18 high-value new licensing deals worth in excess of $500 million took place during the second quarter of 2019 -Get the Q2 2019 Biopharma licensing report for full details and insights. Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: BBK Worldwide Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app. Sponsored by: Blue Latitude Health Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve Sponsored by: Article Galaxy powered by Reprints Desk This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy. Sponsored by: Colorcon® Learn about how you better manage product authentication and battle drug counterfeiting with innovative solutions. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. | 
